Clinical Trials Browser

Pathologic Complete Response

Neoplasm Metastasis, Colorectal Neoplasms

Rectal Neoplasms

Resectable Colon Cancer

Biliary Tract Neoplasms

Cholangiocarcinoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

Carcinoma, Non-Small-Cell Lung

Solid Tumors

Keratosis, Actinic

Colorectal Neoplasms

Colorectal Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Colorectal Neoplasms

Pancreatic Neoplasms

HER2-positive Gastric Cancer

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Advanced Solid Tumor

Stomach Neoplasms

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Locally Advanced Low Rectal Adenocarcinoma

Appendiceal Neoplasms, Colorectal Neoplasms

Pancreatic Neoplasms

Colorectal Neoplasms

Pancreatic Cancer Resectable

Stomach Neoplasms

Biliary Cancer Metastatic

Advanced Small Intestine Cancer

PDAC - Pancreatic Ductal Adenocarcinoma

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Colonic Neoplasms

Nasopharyngeal Carcinoma

Keratosis, Actinic

Colonic Neoplasms, Rectal Neoplasms

Biliary Tract Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Liver Metastases of Colorectal Cancer

Gastroesophageal Junction Cancer

Liver Neoplasms

Efficacy and Safety

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Neoadjuvant Chemotherapy

Breast Neoplasms, Neoplasms, Muscle Neoplasms, Chronic Pain

Rectal Neoplasms

Clinical Trials

MEND-IT II

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

CROCOBIL

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

ARIEL-ENGIC

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

FOXHIPECT4

LEFT-PANC

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

PANORAMIX

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Pre-Operative Treatment in REseCTable COlon CanceR

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

SPRING

Efficacy of Topical 5-Fluorouracil Vs Calcipotriol As Photodynamic Therapy Pre-treatment for Field Actinic Keratoses

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

FD-IMPACT

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

CAPT-02

NASBP-B-09

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy